secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040581
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally
-------------------------------------------------------------------------------

- Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.
- R&D expenses $9.8M, G&A $3.7M in Q2 2023.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling up to 264 subjects globally.
- Phase 2 EFZO-CONNECT study in SSc-ILD expected to start Q3 2023, enrolling 25 patients.
- Received European Commission orphan drug designation for efzofitimod in systemic sclerosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/0000950170-23-040581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/life-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer